Prevalence of venous thromboembolism in medical inpatients

Millar, J Alasdair; Lee, Glenda E; Ienco, Rinaldo

doi:10.5694/j.1326-5377.2010.tb03720.x

Topics

To the Editor: The clinical justification for a medical intervention depends on absolute prevalence (p) of a disease or condition in a population and the relative risk reduction (R) that would result from the intervention. These variables determine the “number needed to treat” (NNT) to prevent one occurrence of a disease, according to the formula NNT = [100 ÷ (P × R)], where P and R are expressed as percentages.

1 Medicine Department, Southland Hospital, Invercargill, New Zealand.
2 Drug Usage and Assessment Group, Royal Perth Hospital, Perth, WA.
3 Finance and Business Services, Royal Perth Hospital, Perth, WA.

Correspondence: alasdair.millar@sdhb.govt.nz

1. National Institute for Clinical Studies. Venous thromboembolism prevention program — the evidence base. http://www.nhmrc.gov.au/nics/programs/vtp/venous.htm (accessed Dec 2009).
2. National Institute of Clinical Studies. The incidence and risk factors for venous thromboembolism in hospitals in Western Australia 1999–2001. Report commissioned from the School of Population Health, University of Western Australia. Canberra: NICS, 2005. http://www.nhmrc.gov.au/nics/material_resources/resources/incident_risk.htm (accessed Dec 2009).
3. Leizorovicz A, Cohen AT, Turpie AG, et al; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
4. Millar JA. Rationale for thromboprophylaxis in medical inpatients; not quite there yet. Med J Aust 2008; 189: 504-506. <MJA full text>
5. Millar JA. Selection of medical patients for prophylaxis of venous thromboembolism based on analysis of the benefit-hazard ratio. Intern Med J 2009; 39: 606-612.

Online responses are no longer available. Please refer to our instructions for authors page for more information.